-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
-
Summary
-
Oncotelic Therapeutics, Inc. quarterly/annual Net Income (Loss) Attributable to Parent history and growth rate from 2010 to 2023.
- Oncotelic Therapeutics, Inc. Net Income (Loss) Attributable to Parent for the quarter ending September 30, 2024 was -$3.3M, a 2966% decline year-over-year.
- Oncotelic Therapeutics, Inc. Net Income (Loss) Attributable to Parent for the twelve months ending September 30, 2024 was -$4.66M, a 62.6% increase year-over-year.
- Oncotelic Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2023 was -$7.9M, a 255% decline from 2022.
- Oncotelic Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2022 was $5.09M.
- Oncotelic Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2021 was -$9.39M, a 1.17% increase from 2020.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Annual (USD)
Net Income (Loss) Attributable to Parent, YoY Annual Growth (%)